Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
Links:
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
https://buff.ly/2VbnLYl
Sep-18-2019
